ApprovedFDA approval

Zycubo (copper histidinate)

Sentynl Therapeutics

Marketer take

The first FDA-approved treatment for Menkes disease, an ultra-rare pediatric copper disorder, so diagnosis in infancy and pediatric neurology and genetics referrals drive the launch.

Sponsor company
Sentynl Therapeutics
Indication
To treat Menkes disease
Therapeutic area
Rare disease
Event
FDA approval
Date
Jan 12, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move